Lilly's Testosterone Lotion Gains U.S. Approval, Pushing Acrux to Record

Acrux Ltd., the developer of an underarm testosterone lotion with Eli Lilly & Co., rose to a record in Australian trading after the treatment was approved for sale in the U.S.

Acrux rose 9.1 percent to A$3.36 as of the 4:10 p.m. close in Sydney, the highest level since the shares listed in September 2004. The stock earlier surged as much as 18 percent.

The U.S. Food and Drug Administration approved the Axiron lotion for men with certain conditions associated with a deficiency or absence of testosterone, Melbourne-based Acrux and Lilly said in a statement dated Nov. 23.

Acrux will receive a payment of $87 million from Lilly, which bought the rights to the drug in March. The Australian company will get royalties and further payments of as much as $195 million from the Indianapolis-based company. Acrux previously said it plans to pay its first dividend to shareholders in early 2011.

Lilly, based in Indianapolis, increased 14 cents, or less than a percent, to $34.22 at 4 p.m. in New York Stock Exchange composite trading.

To contact the reporter on this story: Simeon Bennett in Singapore at sbennett9@bloomberg.net.

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.